Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 726

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 726
---
 the Termination Date.

13. Expenses . All reasonable and documented out-of-pocket costs and expenses incurred by the Shareholder in connection with the negotiation, preparation and execution of this Agreement, the Ancillary

<div align='center'>D-3</div>

TABLE OF CONTENTS

Agreements and the transactions contemplated hereby and thereby, including costs, fees and expenses of the Shareholder’s attorneys, accountants and other advisors, shall constitute SPAC Transaction Expenses (as defined in the Business Combination Agreement) and shall be paid in accordance with the Business Combination Agreement.

14. Nonsurvival of Representations and Warranties . The representations and warranties contained in this Agreement shall not survive the Closing.

15. Adjustment for Stock Split . If, and as often as, there are any changes in the SPAC or the Shareholder Shares by way of stock split, stock dividend, combination or reclassification, or through merger, consolidation, reorganization, recapitalization or business combination, or by any other means, equitable adjustment shall be made to the provisions of this Agreement as may be required so that the rights, privileges, duties and obligations hereunder shall continue with respect to the Shareholder, SPAC, the Company, the Shareholder Shares as so changed.

16. Further Actions . Each of the parties hereto agrees to execute and deliver hereafter any further document, agreement or instrument of assignment, transfer or conveyance as may be necessary or desirable to effectuate the purposes hereof and as may be reasonably requested in writing by another party hereto.

17. No Inconsistent Agreements . The Shareholder hereby covenant and agree that they shall not, at any time prior to the Termination Date, (a) enter into any voting agreement or voting trust with respect to any Shareholder Shares that is inconsistent with their obligations pursuant to this Agreement, (b) grant a proxy or power of attorney with respect to any of the Shareholder Shares that is inconsistent with the Shareholder’s obligations pursuant to this Agreement, or (c) enter into any agreement or undertaking that is otherwise inconsistent with, or would interfere with, or prohibit or prevent from satisfying the Shareholder’s obligations pursuant to this Agreement.

<div align='center'>[remainder of page intentionally left blank]

D-4</div>

TABLE OF CONTENTS

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

| ​ | ​ | ​ | ​ | SPAC:                 |   |   |                 |   |   |